OpenURL Connection Search

Select item for more details and to access through your institution.

Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian-Dutch Study.
Published in:
Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2019, v. 26, n. 2, p. 395, doi. 10.1245/s10434-018-7038-9
By:
- Bertolli, Eduardo;
- Franke, Viola;
- Calsavara, Vinicius Fernando;
- de Macedo, Mariana Petaccia;
- Pinto, Clovis Antonio Lopes;
- van Houdt, Winan J.;
- Wouters, Michel W. J. M.;
- Duprat Neto, Joao Pedreira;
- van Akkooi, Alexander C. J.
Publication type:
Article
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
Published in:
Cancer Immunology, Immunotherapy, 2021, v. 70, n. 8, p. 2291, doi. 10.1007/s00262-020-02839-7
By:
- Stahlie, Emma H. A.;
- Franke, Viola;
- Zuur, Charlotte L.;
- Klop, Willem M. C.;
- van der Hiel, Bernies;
- Van de Wiel, Bart A.;
- Wouters, Michel W. J. M.;
- Schrage, Yvonne M.;
- van Houdt, Winan J.;
- van Akkooi, Alexander C. J.
Publication type:
Article
Challenges in sentinel node pathology in the era of adjuvant treatment.
Published in:
Journal of Surgical Oncology, 2020, v. 122, n. 5, p. 964, doi. 10.1002/jso.26095
By:
- Franke, Viola;
- Madu, Max F.;
- Bierman, Carolien;
- Klop, Willem M. C.;
- Houdt, Winan J.;
- Wouters, Michel W. J. M.;
- Wiel, Bart A.;
- Akkooi, Alexander C. J.
Publication type:
Article
High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a).
Published in:
International Journal of Cancer, 2019, v. 145, n. 4, p. 974, doi. 10.1002/ijc.32172
By:
- Franke, Viola;
- Berger, Danique M.S.;
- Klop, W. Martin C.;
- Hiel, Bernies;
- Wiel, Bart A.;
- Meulen, Sylvia;
- Wouters, Michel W.J.M.;
- Houdt, Winan J.;
- Akkooi, Alexander C.J.
Publication type:
Article
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
Published in:
2022
By:
- Rohaan, Maartje W.;
- Stahlie, Emma H. A.;
- Franke, Viola;
- Zijlker, Lisanne P.;
- Wilgenhof, Sofie;
- van der Noort, Vincent;
- van Akkooi, Alexander C. J.;
- Haanen, John B. A. G.
Publication type:
journal article
A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries.
Published in:
Advances in Therapy, 2021, v. 38, n. 2, p. 1245, doi. 10.1007/s12325-020-01590-w
By:
- van Akkooi, Alexander C. J.;
- Haferkamp, Sebastian;
- Papa, Sophie;
- Franke, Viola;
- Pinter, Andreas;
- Weishaupt, Carsten;
- Huber, Margit A.;
- Loquai, Carmen;
- Richtig, Erika;
- Gokani, Priya;
- Öhrling, Katarina;
- Louie, Karly S.;
- Mohr, Peter
Publication type:
Article

Found: 6

Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian-Dutch Study.

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.

Challenges in sentinel node pathology in the era of adjuvant treatment.

High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a).

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.

A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries.